Trial Profile
Phase II Study of Apatinib in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Apr 2017 New trial record